WellSpan Health to open three CareExpress clinics in York County, Pa.
YORK, Pa. — WellSpan Health is planning to open this fall three CareExpress walk-in health clinics in York County, Pa., of which two clinics will be located inside Giant Food Stores.
According to WellSpan Health’s website, the first clinic is slated to open in DJ Plaza in September. The other two clinic locations will open in October within the Giant Food Stores.
Similar to other retail-based health clinics, WellSpan CareExpress will treat such minor ailments as coughs, colds, ear aches, pink eye and sinusitis, and will offer wellness screenings, immunizations and physicals.
Biogen Idec expands MS ActiveSource
WESTON, Mass. — Biogen Idec has expanded its online resource for patients living with multiple sclerosis to include new resources and support programs.
MS ActiveSource features have expanded to include additional information and support on a range of issues, including financial assistance and nursing services. Additionally, the website also features a new online patient-to-patient community called ActiveVoices.
"Biogen Idec has a long history of partnering with the MS community. Aimed at being the gold standard resource for people living with MS, MS ActiveSource provides extensive services and resources specifically focused on helping people with MS and their families live well while fighting this disease," said Brian Prunier, senior director of Patient Services at Biogen Idec. "With MS ActiveSource, patients and caregivers can easily access financial assistance, insurance counseling, 24/7 nurse support and online resources created specifically with the patient in mind. In addition, our dedicated ActiveSource coordinators offer individual support to help address each patient’s unique needs."
Pfizer to acquire Icagen
NEW YORK — Pfizer has entered a definitive agreement to acquire a biopharmaceutical company that focuses on the development of pain treatments.
Pfizer, which currently owns a near 11% stake in Icagen, will acquire the company’s remaining 8.3 million shares. The aggregate transaction value, which includes the value of the shares currently owned by Pfizer, is about $56 million.
The two companies entered a discovery, development and commercialization collaboration in 2007, which sought to create potential treatments for pain and related disorders.
“We’re excited that Icagen, a global leader in pain research, will join Pfizer, further strengthening our innovative core,” said Ruth McKernan, SVP of Pfizer’s Pain & Sensory Disorders and Regenerative Medicine unit, known as Neusentis. “Icagen’s capabilities and core ion channel technology will help to further expand Pfizer’s position in the pain relief disease area and our ability to develop potential first-in-industry drugs for the treatment of pain and related disorders.”
Pfizer and Icagen expect the deal to be completed by the end of the year.